Skip to main content

Treatment Clinical Trials for Prostate Cancer

Review the prostate cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 151-175 of 302

Elective Pelvic Ultra Hypofractionated Irradiation Treatment with High Dose Rate Brachytherapy Boost for the Treatment of Unfavorable and Higher Risk Prostate Cancer
Status: Active
Location: Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Moderate or Ultra-Hypofractionated Radiation Therapy after Surgery for the Treatment of Prostate Cancer
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Poly-ICLC Vaccine for the Treatment of Prostate Cancer in Patients on Active Surveillance
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Radiation Therapy for the Treatment of Patients with Intermediate-Risk Prostate Cancer, TUMORNATOR I Trial
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
Randomized Phase 2 Trial of Flexible and Extended Dosing of 177Lu-PSMA-617 Molecular Radioligand Therapy (FLEX-MRT)
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Testosterone and ZEN-3694 followed by Enzalutamide and ZEN-3694 for the Treatment of Asymptomatic Patients with Metastatic Castration-Resistant Prostate Cancer, The COSMYC Trial
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Relugolix or Leuprolide for the Treatment of Cardiac Function in Patients with Prostate Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Relugolix in Combination with Radiation Therapy for Treating Patients with High Risk Prostate Cancer
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas
Eflornithine and Testosterone Followed by Enzalutamide for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer, APEX Trial
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Bortezomib for the Treatment of Metastatic Castration-Resistant Prostate Cancer with PTEN Deletion, BORXPTEN Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Status: Active
Location: UCHealth University of Colorado Hospital, Aurora, Colorado
Carboplatin and Cabazitaxel versus Lutetium-177-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, CATCH-177 Trial
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Androgen Deprivation Therapy and SBRT versus SBRT Alone for the Treatment of Unfavorable Intermediate Risk Prostate Cancer
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
Re-treatment with 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Evaluation of Zimberelimab, Etrumadenant, Quemliclustat and Stereotactic Body Radiation Therapy for the Treatment of Hormone Sensitive Oligometastatic Prostate Cancer
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients with Prostate Cancer, HEATWAVE Trial
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Focal Cryotherapy for the Treatment of Intermediate Risk Prostate Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California